Navigation Links
Verification Studies of IntelligentMDx's Proprietary Molecular Diagnostic Assay Process Have Been Completed

CAMBRIDGE, Mass. and COLUMBUS, Ohio, Jan. 8 /PRNewswire/ --IntelligentMDx a developer and manufacturer of proprietary nucleic acid assays, today announced that verification studies of the IntelligentMDx BK Viral Quantitative Assay are complete.

Under the verification protocol the Limit of Detection, linearity, specificity and reproducibility and robustness of the BK Viral Quantitative Assay were determined. The data obtain agreed with internally generated analytical performance data generated at IntelligentMDx. The data was consistent with data obtained from external clinical data obtained from Washington University that was presented at the 14th Annual Meeting of the Association for Molecular Pathology. The verification studies were performed at Battelle.

Based upon the data obtained the assay was shown to have a Limit of Detection of 8 copies of BK target per assay. The assay was linear over the 5 log range that was tested having an R-squared value is 0.99; this calculates to an amplification efficiency of 94.5%. In addition the specificity (false negative rate) for the assay was shown to be 100% for the limited number of true negatives assessed. Precision and robustness testing showed that the test was highly precise and robust with inconsequential variation observed in day-to-day and tech-to-tech testing. Analysis of the standard quantitative curves for each plate run (n=14) showed an average slope is -3.37 with a 95 percent confidence interval of (-3.47, -3.27) with all R-squared values are above 0.99 with the exception of one plate.

About IntelligentMDx

IntelligentMDx's mission is to make FDA approved diagnostic kits. To guarantee quality for customers and partners we design, develop and manufacture tests under FDA Quality System Regulations and ISO 13485:2003 guidelines. These tests have been, and will be, designed to run on a broad range of molecular systems for clinical diagnostics, drug development and applied sciences.

IntelligentMDx's competitive advantage is in the production of superior performing tests with significantly faster time to market than other approaches. Embedded in the approach is an intelligent technology that uses mathematical algorithms to predict test failure and simulate real life conditions such as contamination or genetic mutations, that would impact test functionality. IntelligentMDx's current pipeline includes proprietary nucleic acid (DNA or RNA) tests for Real Time PCR. These tests cover a range of important infectious diseases and are designed to drive the clinical decision making process, maximizing impact on patient care.

About Battelle

Battelle's Global Health and Life Sciences business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms. Including the national laboratories it manages or co-manages, Battelle oversees over $200 million annually in health and life sciences-research contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

Statements in this release, including but not limited to those that may relate to revenue growth, trends in financial or operational performance, litigation, new product plans and business prospects are forward-looking statements. Actual results might differ materially from these statements due to risks and uncertainties, including the impact of competitive products and pricing, market acceptance of new products, market conditions and enforcement of intellectual property rights. A more detailed description of these risks and other risks applicable to IntelligentMDx are available upon request from IntelligentMDx. IntelligentMDx disclaims any intent or obligation to update these forward-looking statements.

CONTACT: For more information on IntelligentMDx, visit or contact Corporate Communications at, 617-871-6400.

For more information on Battelle, visit or contact Public Relations Manager Katy Delaney at (410) 306-8638 or at

SOURCE IntelligentMDx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
4. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
5. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
6. Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder
7. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
10. Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting
11. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
Post Your Comments:
(Date:11/29/2015)... 2015  The GE Health Cloud 1 was unveiled ... North America (RSNA) meeting in ... the new cloud ecosystem and its applications will connect radiologists ... and multidisciplinary teams – both inside and outside the hospital ... of GE. "As the digital industrial leader, we are betting ...
(Date:11/27/2015)... November 27, 2015 --> ... to go online. The potential to save costs, improve ... and far from fully exploited as yet. Here, particular ... records, either via mobile tablet or directly at the ... ) -->      (Photo: ...
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
Breaking Medicine Technology:
(Date:11/27/2015)... Denver, CO (PRWEB) , ... November 27, 2015 , ... ... U.S. cities are not changing the way that they are handling security in light ... increasing police and security presence in an attempt to stop an attack from reaching ...
(Date:11/27/2015)... ... ... A team of Swiss doctors has released a report on mesothelioma relapse and ... findings on the website. Click here to read the details now. ... were treated with chemotherapy followed by EPP surgery. Among the 106 patients who relapsed, ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I was traveling, I ... Hillside, N.J. "Many people catch diseases simply from sitting on such dirty toilet ... protected from germs." , He developed the patent-pending QUDRATECS to eliminate the need ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, ... Table 1-1 ). More than 3.7 billion people under the age of 50 – ... according to WHO's first global estimates of HSV-1 infection . , "The data shocks ...
Breaking Medicine News(10 mins):